Scopolamine Transdermal Patch Dosage
Apply one 1.5 mg scopolamine transdermal patch to the hairless area behind one ear, which delivers approximately 1 mg of scopolamine over 3 days at a rate of 5 mcg/hour. 1
Application Protocol
Timing
- For motion sickness: Apply at least 4 hours before antiemetic effect is needed (optimal protection begins 6-8 hours post-application) 1
- For postoperative nausea/vomiting (PONV): Apply the evening before scheduled surgery; remove 24 hours after surgery 1
Application Instructions
- Apply to hairless postauricular area (behind one ear) on clean, dry skin 1
- Wash hands thoroughly with soap and water immediately after application to prevent accidental eye contamination 1
- Wear only one patch at a time; do not cut the patch 1
- If patch becomes displaced, discard and apply new patch behind the other ear 1
- Avoid touching or applying pressure to patch while worn 1
Duration and Replacement
- Maximum duration: 3 days per patch 1
- For therapy >3 days: Remove first patch and apply new patch behind the opposite ear 1
- Upon removal, fold patch in half (sticky sides together) and discard safely 1
- Wash hands and application site with soap and water after removal 1
Dosing for Breakthrough Nausea/Vomiting
For chemotherapy-induced or refractory nausea/vomiting, scopolamine 1.5 mg transdermal patch is applied every 72 hours as an adjunctive agent 2, 3. This is used when other antiemetics have failed, not as first-line therapy.
Pharmacokinetics
- Therapeutic plasma concentration: 50-100 pg/mL 4, 5
- Time to therapeutic level: 6-8 hours (steady-state at 8-12 hours) 4, 6
- Peak concentration: ~100 pg/mL (range 11-240 pg/mL) at 8 hours 4, 6
- Priming dose: 140 mcg in adhesive layer accelerates achievement of steady-state 4, 6
Important caveat: 20-30% of patients fail to achieve protective plasma concentrations, which may explain treatment failures 4. Non-responders have significantly lower plasma levels (97 pg/mL) compared to responders (157 pg/mL) 5.
Contraindications
- Angle-closure glaucoma (absolute contraindication) 1
- Hypersensitivity to scopolamine, belladonna alkaloids, or formulation components 1
Critical Warnings
Acute Angle-Closure Glaucoma
Monitor patients with open-angle glaucoma; mydriatic effect can increase intraocular pressure 1. Instruct patients to remove patch immediately if they experience eye pain, blurred vision, visual halos, red eyes, or corneal edema 1.
Neuropsychiatric Effects
- Psychiatric reactions: Can exacerbate psychosis; monitor for agitation, hallucinations, paranoia, delusions 1
- Seizures: Use cautiously in patients with seizure history or risk factors 1
- Cognitive impairment: Can cause drowsiness, disorientation, confusion 1
- Elderly and pediatric patients are more sensitive to neuropsychiatric effects 1
- Remove patch immediately if psychiatric or cognitive symptoms develop 1
Hand Contamination Risk
The most common pitfall is finger-to-eye contamination causing mydriasis and cycloplegia 4, 6. This is why meticulous handwashing after application and removal is critical 1.
Adverse Effects
- Dry mouth: 50-60% of patients 4
- Drowsiness: Up to 20% 4
- Allergic contact dermatitis: 10% 4
- Transient visual impairment: Accommodation difficulties, mydriasis 4, 6
- Onset of transdermal patch benefit for secretions: ~12 hours, making it inappropriate for imminently dying patients 7
Special Populations
Pregnancy and Lactation
Scopolamine crosses the placenta; use only under observation in pregnant women 6. Compatible with breastfeeding and considered non-teratogenic 6.
Refractory Cases
For patients who fail single-patch therapy (non-responders with plasma levels <100 pg/mL), double-dose therapy (two patches) has been studied and found safe, achieving mean plasma concentrations of 127 pg/mL vs. 81 pg/mL with single dose, without significant increase in adverse effects beyond mild blurred vision 8, 5. However, this is off-label use.
Rapid Onset Strategy
For faster protection when <6 hours available before exposure, combine transdermal patch with oral scopolamine 0.3-0.6 mg, which achieves therapeutic levels within 0.5-1 hour without significant additional adverse effects 9. This combination is well-tolerated and effective.